StocksMedium•7 October 2026•
1 min read
UK Revokes Marketing Authorization for Valneva's IXCHIQ Vaccine
Key Facts
1The UK Medicines and Healthcare products Regulatory Agency (MHRA) has revoked the marketing authorization for the IXCHIQ vaccine.
2The decision was based on a review of previous safety data and was not associated with any newly identified safety signal.
3The company stated the decision does not affect product licenses in the EU, Canada, Brazil, or other territories.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has revoked the marketing authorization for Valneva's IXCHIQ vaccine. According to a company statement via GlobeNewswire, the decision followed a further benefit-risk assessment by the Commission on Human Medicines (CHM). The company noted that the revocation was based on a review of existing safety data and was not associated with any newly identified safety signals.
Valneva stated that the UK decision does not affect its product licenses in other territories, including the European Union, Canada, and Brazil. Regarding market performance, VALN closed at $5.86 on October 6, 2026, having traded between a day high of $6.04 and a day low of $5.78 during that session.